Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC
Kwan Ho Tang, Shuai Li, Alireza Khodadadi‐Jamayran, et al.
Cancer Discovery (2021) Vol. 12, Iss. 1, pp. 47-61
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

The current state of the art and future trends in RAS-targeted cancer therapies
Salman R. Punekar, Vamsidhar Velcheti, Benjamin G. Neel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 10, pp. 637-655
Open Access | Times Cited: 306
Therapeutic targeting of tumour myeloid cells
Simon T. Barry, Dmitry I. Gabrilovich, Owen J. Sansom, et al.
Nature reviews. Cancer (2023) Vol. 23, Iss. 4, pp. 216-237
Closed Access | Times Cited: 152
CXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie, John B. G. Mackey, Thomas Jamieson, et al.
Gut (2022) Vol. 71, Iss. 10, pp. 2093-2106
Open Access | Times Cited: 122
Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis
Yulan Mo, Leanne Lee Leung, Celia S. L. Mak, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 62
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment
Nicole M. Sodir, Gaurav Pathria, Joanne I. Adamkewicz, et al.
Cancer Discovery (2023) Vol. 13, Iss. 11, pp. 2339-2355
Open Access | Times Cited: 43
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
Junli Lu, Yiming Luo, Dean Rao, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 39
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 28
Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization
Zhiyong Xu, Chunyi Guo, Qiaoli Ye, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 76
Clonal lineage tracing reveals shared origin of conventional and plasmacytoid dendritic cells
Jue Feng, Joseph N. Pucella, Geunhyo Jang, et al.
Immunity (2022) Vol. 55, Iss. 3, pp. 405-422.e11
Open Access | Times Cited: 67
Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
Robby Barnestein, Loïck Galland, Laura Kalfeist, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 57
Transitional dendritic cells are distinct from conventional DC2 precursors and mediate proinflammatory antiviral responses
Fernando Bandeira Sulczewski, Raúl Antonio Maqueda‐Alfaro, Marcela Alcántara‐Hernández, et al.
Nature Immunology (2023) Vol. 24, Iss. 8, pp. 1265-1280
Closed Access | Times Cited: 33
CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells
Yuhan Zhang, Junyi Hu, Kai Ji, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 8, pp. 101151-101151
Open Access | Times Cited: 26
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1352-1370
Open Access | Times Cited: 10
EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas
Tanner J. DuCote, Xiulong Song, Kassandra J. Naughton, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 2, pp. 388-403
Open Access | Times Cited: 8
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors
Shoiab Bukhari, Brian S. Henick, Robert Winchester, et al.
Cell Reports Medicine (2022) Vol. 4, Iss. 1, pp. 100868-100868
Open Access | Times Cited: 37
Dissecting the brain with spatially resolved multi-omics
Yijia Fangma, Mengting Liu, Jie Liao, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 13, Iss. 7, pp. 694-710
Open Access | Times Cited: 21
Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response
Emily K. Kleczko, Anh T. Le, Trista K. Hinz, et al.
Cancer Letters (2023) Vol. 556, pp. 216062-216062
Open Access | Times Cited: 17
CXCR2 chemokine receptor – a master regulator in cancer and physiology
Gwendal Lazennec, Krishna Rajarathnam, Ann Richmond
Trends in Molecular Medicine (2023) Vol. 30, Iss. 1, pp. 37-55
Open Access | Times Cited: 17
SHP2 as a primordial epigenetic enzyme expunges histone H3 pTyr-54 to amend androgen receptor homeostasis
Surbhi Chouhan, Dhivya Sridaran, Cody Weimholt, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?
Xun Chen, S. Keller, Philipp Hafner, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors
Pei Zhang, Yang Du, Hua Bai, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 24
MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation
Yuan Wang, Zhenchang Jia, Chenxi Liang, et al.
Cell Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 14
Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer
Qianmiao Wu, Huaijun Tu, Jian Li
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Targeting tumor microenvironment for non-small cell lung cancer immunotherapy
Lei Wang, Qingzhu Jia, Qian Chu, et al.
Chinese Medical Journal - Pulmonary and Critical Care Medicine (2023) Vol. 1, Iss. 1, pp. 18-29
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top